EUVIMEDEUVIMED entdecken
Crossref

COVID ‐19 associated thrombotic microangiopathy

Esra Karabag Yilmaz iD, Memnune Nur Cebi iD, Iremnaz Karahan, Seha Saygılı iD, Ruveyda Gulmez iD, Ebru Burcu Demirgan iD, Cansu Durak iD, Fatih Aygun iD, Fatih Ozaltin iD, Salim Caliskan iD, Nur Canpolat iD

Nephrology · 2023

DOI: 10.1111/nep.14225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, 2023. Verfasst von Esra Karabag Yilmaz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Nephrology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: COVID-19, Thrombotic Microangiopathies, Purpura, Thrombotic Thrombocytopenic, Acute Kidney Injury. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A limited number of cases of thrombotic microangiopathy (TMA) have previously been reported in association with COVID‐19. Our report describes two cases of TMA associated with COVID‐19, one of which was successfully treated with eculizumab. The first case was a 23‐month‐old girl, and the second case was a 9‐month‐old boy. PCR tests for SARS‐CoV‐2 were positive in both cases, and laboratory results showed microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury. No known aetiology for TMA was found in either case. Stool tests for Shigatoxin‐producing Escherichia coli were negative. Coagulation tests, ADAMTS13 activity, serum complement levels, and homocysteine levels were all within the normal range. No known genetic mutation was found, including mutations of complement, diacylglycerol kinase epsilon, and cobalamin C. In the first case, eculizumab was administered due to persistent haemolysis and prolonged anuria. In conclusion, TMA may be associated with COVID‐19 infection. Treatment with eculizumab may be beneficial in selected patients because of the potential activation of the complement system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Thrombotic MicroangiopathiesPurpura, Thrombotic ThrombocytopenicAcute Kidney InjuryMaleFemaleHumansInfantChild, PreschoolSARS-CoV-2

Stichwörter der Autor:innen

COVID-19HUSTMAeculizumabthrombotic microangiopathy

Autor:innen und Institutionen

  • Department of Paediatric Nephrology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
  • Department of Paediatrics, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
  • Department of Paediatric Nephrology, Istanbul Training and Research Hospital, Istanbul, Turkey.
  • Department of Paediatric Intensive Care Unit, Sancaktepe Sehit Prof. Dr. İlhan Varank Training and Research Hospıtal, Istanbul, Turkey.
  • Department of Paediatric Intensive Care Unit, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
  • Nephrogenetics Laboratory, Department of Pediatrics, Hacettepe University School of Medicine, Ankara, Turkey.

ORCID-Profile: Esra Karabag Yilmaz, Memnune Nur Cebi, Seha Saygılı, Ruveyda Gulmez, Ebru Burcu Demirgan, Cansu Durak, Fatih Aygun, Fatih Ozaltin, Salim Caliskan, Nur Canpolat

Zitieren

APA

Karabag Yilmaz, E., Cebi, M. N., Karahan, I., Saygılı, S., Gulmez, R., Demirgan, E. B., Durak, C., Aygun, F., Ozaltin, F., Caliskan, S., & Canpolat, N. (2023). COVID ‐19 associated thrombotic microangiopathy. Nephrology. https://doi.org/10.1111/nep.14225

Vancouver

Karabag Yilmaz E, Cebi MN, Karahan I, Saygılı S, Gulmez R, Demirgan EB, et al. COVID ‐19 associated thrombotic microangiopathy. Nephrology. 2023. doi:10.1111/nep.14225

BibTeX
@article{KarabagYilmaz2023,
  author = {Karabag Yilmaz, Esra and Cebi, Memnune Nur and Karahan, Iremnaz and Saygılı, Seha and Gulmez, Ruveyda and Demirgan, Ebru Burcu and Durak, Cansu and Aygun, Fatih and Ozaltin, Fatih and Caliskan, Salim and Canpolat, Nur},
  title = {COVID ‐19 associated thrombotic microangiopathy},
  journal = {Nephrology},
  year = {2023},
  doi = {10.1111/nep.14225}
}
Kostenlos starten →